Loading...

AVTX AVALO THERAPEUTICS INC Product Launches 8-K Filing

VL T

VTX

AVALO THERAPEUTICS INC

(AVTX)

2024 8-K

Board Departures

Financial Results Announcement

Financial Update

Investor Presentation Update

Financial Results Announced

Enrollment Complete

Investor Presentation Update

New Executive Appointment

Financial Statements

Equity Offerings

Investor Meetings

Financial Statements

Investor Meetings

Board Appointment

Financial Results

Investor Presentation

Management Change

Investor Update

Warrant Exercise

Financial Results

Trial Announcement

Investor Update

Nasdaq Compliance

Equity Plans Update

Financial Results

Notice from Nasdaq

Appointment of Chief Medica...

Appointment of Chief Legal ...

Amendment to Previous Report

Amendment to 8-K

Delisting Notice

Financial Results Announcement

Financial Results Announcement

Merger and Reorganization

Compliance with Nasdaq bid ...

Reverse Stock Split

Annual Meeting Results

Financial Results Announcement

Completion of Asset Sale

Bylaws Amendment

Annual Meeting of Stockholders

Forbearance Agreement and L...

Sales Agreement Amendment

Financial Results Announcement

Debt Restructuring

Announcement of Phase 2 Tri...

Exchange Agreement with Ven...

Sales Agreement

Financial Results Announcement

Termination of Sales Agreement

Financial Results Announcement

Investor Presentation

Public Offering

Completion of Phase 2 PEAK ...

External Links:

Avalo Therapeutics announced that the first patient has been dosed in its Phase 2 LOTUS Trial for AVTX-009, a treatment for hidradenitis suppurativa, and released an updated investor presentation.

AI Assistant

AVALO THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.